Human methylome studies SRP504106 Track Settings
 
Mutant IDH1 inhibition induces reverse transcriptase and dsDNA sensing to activate tumor immunity [human WGBS] [Tumor Cells]

Track collection: Human methylome studies

+  All tracks in this collection (424)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       CpG reads ▾       PMD       CpG methylation ▾      
Select subtracks by views and experiment:
 All views AMR  CpG reads  PMD  CpG methylation 
experiment
SRX24373100 
SRX24373101 
SRX24373102 
SRX24373103 
SRX24373104 
SRX24373105 
SRX24373106 
SRX24373107 
SRX24373108 
SRX24373109 
SRX24373110 
SRX24373111 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX24373100  CpG methylation  Tumor Cells / SRX24373100 (CpG methylation)   Data format 
hide
 Configure
 SRX24373101  CpG methylation  Tumor Cells / SRX24373101 (CpG methylation)   Data format 
hide
 Configure
 SRX24373102  CpG methylation  Tumor Cells / SRX24373102 (CpG methylation)   Data format 
hide
 Configure
 SRX24373103  CpG methylation  Tumor Cells / SRX24373103 (CpG methylation)   Data format 
hide
 Configure
 SRX24373104  CpG methylation  Tumor Cells / SRX24373104 (CpG methylation)   Data format 
hide
 Configure
 SRX24373105  CpG methylation  Tumor Cells / SRX24373105 (CpG methylation)   Data format 
hide
 Configure
 SRX24373106  CpG methylation  Tumor Cells / SRX24373106 (CpG methylation)   Data format 
hide
 Configure
 SRX24373107  CpG methylation  Tumor Cells / SRX24373107 (CpG methylation)   Data format 
hide
 Configure
 SRX24373108  CpG methylation  Tumor Cells / SRX24373108 (CpG methylation)   Data format 
hide
 Configure
 SRX24373109  CpG methylation  Tumor Cells / SRX24373109 (CpG methylation)   Data format 
hide
 Configure
 SRX24373110  CpG methylation  Tumor Cells / SRX24373110 (CpG methylation)   Data format 
hide
 Configure
 SRX24373111  CpG methylation  Tumor Cells / SRX24373111 (CpG methylation)   Data format 
    
Assembly: Human Dec. 2013 (GRCh38/hg38)

Study title: Mutant IDH1 inhibition induces reverse transcriptase and dsDNA sensing to activate tumor immunity [human WGBS]
SRA: SRP504106
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX24373100 Tumor Cells 0.636 12.2 76305 12411.0 801 1002.6 4921 224593.2 0.984 GSM8230087: WGBS, SNU1079 in vitro, DMSO, Replicate 1; Homo sapiens; Bisulfite-Seq
SRX24373101 Tumor Cells 0.634 13.2 78022 12224.5 928 999.1 4943 223911.7 0.985 GSM8230088: WGBS, SNU1079 in vitro, DMSO, Replicate 2; Homo sapiens; Bisulfite-Seq
SRX24373102 Tumor Cells 0.634 12.8 77577 12266.8 875 1005.9 4930 224360.2 0.985 GSM8230089: WGBS, SNU1079 in vitro, DMSO, Replicate 3; Homo sapiens; Bisulfite-Seq
SRX24373103 Tumor Cells 0.637 12.1 77003 12308.1 790 992.9 4868 226831.7 0.984 GSM8230090: WGBS, SNU1079 in vitro, IFNg, Replicate 1; Homo sapiens; Bisulfite-Seq
SRX24373104 Tumor Cells 0.636 13.1 78107 12170.9 882 1011.3 4898 225898.6 0.984 GSM8230091: WGBS, SNU1079 in vitro, IFNg, Replicate 2; Homo sapiens; Bisulfite-Seq
SRX24373105 Tumor Cells 0.635 12.4 77139 12287.5 873 1016.1 4894 225670.4 0.985 GSM8230092: WGBS, SNU1079 in vitro, IFNg, Replicate 3; Homo sapiens; Bisulfite-Seq
SRX24373106 Tumor Cells 0.526 12.3 70065 12218.0 3907 992.4 4793 208493.3 0.985 GSM8230093: WGBS, SNU1079 in vitro, AG120, Replicate 1; Homo sapiens; Bisulfite-Seq
SRX24373107 Tumor Cells 0.525 12.4 70625 12136.9 3965 981.4 4737 210648.5 0.986 GSM8230094: WGBS, SNU1079 in vitro, AG120, Replicate 2; Homo sapiens; Bisulfite-Seq
SRX24373108 Tumor Cells 0.529 12.4 70865 12117.2 3969 976.4 4746 210026.9 0.985 GSM8230095: WGBS, SNU1079 in vitro, AG120, Replicate 3; Homo sapiens; Bisulfite-Seq
SRX24373109 Tumor Cells 0.460 11.6 66366 12788.3 9951 1058.5 4639 209510.6 0.986 GSM8230096: WGBS, SNU1079 in vitro, AG120+IFNg, Replicate 1; Homo sapiens; Bisulfite-Seq
SRX24373110 Tumor Cells 0.465 11.4 66309 12806.2 10216 1062.2 4608 210372.5 0.986 GSM8230097: WGBS, SNU1079 in vitro, AG120+IFNg, Replicate 2; Homo sapiens; Bisulfite-Seq
SRX24373111 Tumor Cells 0.463 11.9 67404 12537.6 14496 1140.9 3588 274645.8 0.984 GSM8230098: WGBS, SNU1079 in vitro, AG120+IFNg, Replicate 3; Homo sapiens; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.